Comments on 'Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design' by Satoshi Morita and Junichi Sakamoto. Pharmaceutical Statistics.
In this commentary, we show that the treatment selection probabilities in Morita and Sakamoto [1] could be different if safety information is considered.